Twist Bioscience Corporation Capital Expenditures
Twist Bioscience Corporation (TWST) reported Capital Expenditures of $27.62 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-03
- Twist Bioscience Corporation payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $9.76M, a 6.52% increase year-over-year.
- Twist Bioscience Corporation payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $7.89M, a 90.32% increase year-over-year.
- Twist Bioscience Corporation payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $9.97M, a 339.77% increase year-over-year.
- Twist Bioscience Corporation payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $12.43M, a 520.73% increase year-over-year.
- Twist Bioscience Corporation payments to acquire property, plant, and equipment for fiscal 2025 was $28.00M, a 451.69% increase from fiscal 2024.
- Twist Bioscience Corporation payments to acquire property, plant, and equipment for fiscal 2024 was $5.08M, a 81.73% decline from fiscal 2023.
- Twist Bioscience Corporation payments to acquire property, plant, and equipment for fiscal 2023 was $27.78M, a 72.73% decline from fiscal 2022.
- Twist Bioscience Corporation payments to acquire property, plant, and equipment for fiscal 2022 was $101.86M, a 276.40% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-03 | $17.65M derived: sum of 2 quarters · filed 2026-08-03 | $27.62M 10-Q · filed 2026-08-03 | $40.05M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $7.89M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-05-04 | $17.86M 10-Q · filed 2026-05-04 | $30.29M derived: sum of 3 quarters · filed 2026-05-04 | $39.45M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $9.97M 10-Q/A · filed 2026-02-26 | $22.40M derived: sum of 2 quarters · filed 2026-02-26 | $31.57M derived: sum of 3 quarters · filed 2026-08-03 | $35.71M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-09-30 | $12.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $21.59M derived: sum of 2 quarters · filed 2026-08-03 | $25.74M derived: sum of 3 quarters · filed 2026-08-03 | $28.00M 10-K · filed 2025-11-17 |
| 2025-06-30 | $9.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-03 | $13.31M derived: sum of 2 quarters · filed 2026-08-03 | $15.58M 10-Q · filed 2026-08-03 | $17.58M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $4.14M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-05-04 | $6.41M 10-Q · filed 2026-05-04 | $8.41M derived: sum of 3 quarters · filed 2026-05-04 | $9.38M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $2.27M 10-Q/A · filed 2026-02-26 | $4.27M derived: sum of 2 quarters · filed 2026-02-26 | $5.24M derived: sum of 3 quarters · filed 2026-02-26 | $5.84M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-09-30 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $2.97M derived: sum of 2 quarters · filed 2025-11-17 | $3.57M derived: sum of 3 quarters · filed 2025-11-17 | $5.08M 10-K · filed 2025-11-17 |
| 2024-06-30 | $965.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-04 | $1.57M derived: sum of 2 quarters · filed 2025-08-04 | $3.07M 10-Q · filed 2025-08-04 | $5.47M derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-03-31 | $603.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-05 | $2.11M 10-Q · filed 2025-05-05 | $4.50M derived: sum of 3 quarters · filed 2025-11-17 | $9.01M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-12-31 | $1.51M 10-Q · filed 2025-02-03 | $3.90M derived: sum of 2 quarters · filed 2025-11-17 | $8.41M derived: sum of 3 quarters · filed 2025-11-17 | $17.46M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-09-30 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $6.90M derived: sum of 2 quarters · filed 2025-11-17 | $15.96M derived: sum of 3 quarters · filed 2025-11-17 | $27.78M 10-K · filed 2025-11-17 |
| 2023-06-30 | $4.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-02 | $13.56M derived: sum of 2 quarters · filed 2024-08-02 | $25.39M 10-Q · filed 2024-08-02 | $41.85M derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-03-31 | $9.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-02 | $20.88M 10-Q · filed 2024-05-02 | $37.34M derived: sum of 3 quarters · filed 2024-11-18 | $77.98M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-12-31 | $11.82M 10-Q · filed 2024-02-02 | $28.29M derived: sum of 2 quarters · filed 2024-11-18 | $68.93M derived: sum of 3 quarters · filed 2024-11-18 | $100.90M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-09-30 | $16.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | $57.10M derived: sum of 2 quarters · filed 2024-11-18 | $89.07M derived: sum of 3 quarters · filed 2024-11-18 | $101.86M 10-K · filed 2024-11-18 |
| 2022-06-30 | $40.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | $72.61M derived: sum of 2 quarters · filed 2023-08-07 | $85.39M 10-Q · filed 2023-08-07 | $93.48M derived: sum of 4 quarters · filed 2023-11-21 |
| 2022-03-31 | $31.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-08 | $44.75M 10-Q · filed 2023-05-08 | $52.84M derived: sum of 3 quarters · filed 2023-11-21 | $59.78M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-12-31 | $12.78M 10-Q · filed 2023-02-07 | $20.87M derived: sum of 2 quarters · filed 2023-11-21 | $27.81M derived: sum of 3 quarters · filed 2023-11-21 | $36.22M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-09-30 | $8.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | $15.03M derived: sum of 2 quarters · filed 2023-11-21 | $23.43M derived: sum of 3 quarters · filed 2023-11-21 | $27.06M 10-K · filed 2023-11-21 |
| 2021-06-30 | $6.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08 | $15.34M derived: sum of 2 quarters · filed 2022-08-08 | $18.97M 10-Q · filed 2022-08-08 | $21.20M derived: sum of 4 quarters · filed 2023-06-05 |
| 2021-03-31 | $8.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-06 | $12.03M 10-Q · filed 2022-05-06 | $14.26M derived: sum of 3 quarters · filed 2023-06-05 | $17.10M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-12-31 | $3.63M 10-Q · filed 2022-02-09 | $5.85M derived: sum of 2 quarters · filed 2023-06-05 | $8.70M derived: sum of 3 quarters · filed 2023-06-05 | $11.44M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-09-30 | $2.23M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | $5.07M derived: sum of 2 quarters · filed 2023-06-05 | $7.81M derived: sum of 3 quarters · filed 2023-06-05 | $9.87M 10-K/A · filed 2023-06-05 |
| 2020-06-30 | $2.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-09 | $5.58M derived: sum of 2 quarters · filed 2021-08-09 | $7.64M 10-Q · filed 2021-08-09 | $11.54M derived: sum of 4 quarters · filed 2021-11-23 |
| 2020-03-31 | $2.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-07 | $4.79M 10-Q · filed 2021-05-07 | $8.69M derived: sum of 3 quarters · filed 2021-11-23 | $13.86M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-12-31 | $2.06M 10-Q · filed 2021-02-09 | $5.95M derived: sum of 2 quarters · filed 2021-11-23 | $11.12M derived: sum of 3 quarters · filed 2021-11-23 | $14.89M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-09-30 | $3.89M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-23 | $9.06M derived: sum of 2 quarters · filed 2021-11-23 | $12.84M derived: sum of 3 quarters · filed 2021-11-23 | $14.76M 10-K · filed 2021-11-23 |
| 2019-06-30 | $5.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-12 | $8.94M derived: sum of 2 quarters · filed 2020-08-12 | $10.86M 10-Q · filed 2020-08-12 | $11.91M derived: sum of 4 quarters · filed 2020-11-27 |
| 2019-03-31 | $3.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-13 | $5.69M 10-Q · filed 2020-05-13 | $6.74M derived: sum of 3 quarters · filed 2020-11-27 | $7.37M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-12-31 | $1.92M 10-Q · filed 2020-02-10 | $2.97M derived: sum of 2 quarters · filed 2020-11-27 | $3.60M derived: sum of 3 quarters · filed 2020-11-27 | $4.10M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-09-30 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-27 | $1.68M derived: sum of 2 quarters · filed 2020-11-27 | $2.18M derived: sum of 3 quarters · filed 2020-11-27 | $3.69M 10-K · filed 2020-11-27 |
| 2018-06-30 | $629.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09 | $1.13M derived: sum of 2 quarters · filed 2019-08-09 | $2.64M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $501.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-02 | $2.01M 10-Q · filed 2019-05-02 | ||
| 2017-12-31 | $1.51M 10-Q · filed 2019-02-11 | |||
| 2017-09-30 | $6.59M 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |